Email This Article

TheStreet Picks
Biotech Notebook: Onyx, Genentech, Cardiome
By Adam Feuerstein
02/20/08 - 06:53 AM EST
Onyx's increased spending is even more troubling than its failed Nexavar trial. Elsewhere, Genentech faces a key FDA decision.
Recipient's Email Address(es)
(Separate multiple addresses with a comma)
Your Email Address
Send a copy to myself
Your Message (optional)

Privacy Policy

The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.

Your Recent Quotes: Quote Up0 | Quote Down0
Dow S&P 500 NASDAQ
Oil*
Gold
10 Yr
0.00%
%
%
%
Data delayed 20 min
Sign up for our FREE newsletters now. See All

  • Cramer's Daily Booyah!
  • Before the Bell
Submit Privacy Policy

Premium Stock Ideas
Find more premium investing ideas